ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, Rapidly Controls Inflammation and Improves 2-Month Survival in Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis

Field: Medicine (Health Sciences)

Introduction: ELA026 is a first-in-class human monoclonal antibody directed against signal regulatory protein (SIRP)α/β1/γ and is under clinical investigation in secondary hemophagocytic lymphohistiocytosis (sHLH). sHLH is a life-threatening hyperinflammatory condition caused by failure to terminate the activation and proliferation of natural killer (NK), T cells and macrophages after an initial immune response. There are no approved therapies for sHLH. With a mortality rate of approximately 50% at 2 months (Lionel et al. 2023), malignancy-associated HLH (mHLH) is the deadliest subtype of sHLH. Cytotoxic, multi-agent chemotherapy (including etoposide) does not address the poor prognosis associated with mHLH (Xie et al. 2013). Directly targeting the pathogenic SIRP(+) myeloid cells and T lymphocytes represents a novel approach to resolving this severe hyperinflammatory condition. Methods: This is an open-label, single-arm, Phase 1b global multicenter study (NCT05416307) evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of ELA026 in adult and pediatric patients with newly diagnosed and previously treated sHLH. The study is expanding enrollment to evaluate a fixed-dose regimen consisting of a priming phase of 0.1 mg/kg Day 1 and 0.3 mg/kg Days 2-4, followed by a maintenance phase of 0.5 mg/kg twice weekly beginning on Day 8. ELA026 is administered intravenously, with the option to transition to subcutaneous administration upon hospital discharge. The treatment period is 12 weeks with the option to extend in patients deriving ongoing clinical benefits. Enrollment in this cohort is restricted to frontline settings based on the experience that relapsed/refractory sHLH patients exhibited poor survival even with HLH disease control and died from complications related to severe baseline comorbidities. Response is evaluated using a modified HLH-2004 criteria (Locatelli et al. 2020) and survival is calculated from the time of HLH diagnosis. All patients receive dexamethasone as background therapy and premedication initially. Patients with mHLH may also receive cancer-directed therapies concurrently. Primary pharmacodynamic (PD) effects (monocyte and lymphocyte reduction) and secondary PD effects (C-reactive protein [CRP], ferritin, and sCD25 reduction) were best evaluated and attributed to ELA026 during windows of treatment without concurrent chemotherapy effects. Results: As of July 15, 2024, 12 treatment-naïve mHLH patients have enrolled in all cohorts of the study, with a median age of 47 years (range 21-78). The following malignancies were represented: 7 T-cell lymphoma, 2 DLBCL, 1 AML, 1 Hodgkin lymphoma, and 1 T-cell ALL. In this group, response rate was 100% with 2 mCR and 9 PR by Week 4 and survival was 88% at 2 months (7/8; 4 patients are alive and have not reached 2 months on study). Median survival has not been reached; median follow-up is 2.3 months (range 0.1-15.9 months). In terms of PD effects, monocyte and lymphocyte reduction generally occurred following the first priming dose and ferritin and CRP were reduced by an average of 40% and 50% by Day 6, respectively, for patients with windows of ELA026 treatment without concurrent chemotherapy effects. Study-wide (all patients dosed), treatment-related infusion reactions (~20%) and cytopenias (~30%) were generally manageable with supportive care and dosing modifications. One serious adverse event, a grade 4 infusion reaction, was assessed as related in a relapsed/refractory mHLH patient with acute liver failure and poor hemodynamic reserve. Infection risks are expected for this patient population, which were mitigated with growth factor support and antimicrobial prophylaxis. No deaths were related to study drug. Updated study results will be provided at the 2024 ASH meeting in San Diego. Conclusion: Data suggest ELA026 is well-tolerated to date in sHLH patients and results in a 100% response rate and improved 2-month survival in treatment-naïve mHLH patients. The study is enrolling in an expanded cohort to further assess efficacy in this patient population.